Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021
HomeMEDTRONIC plcCommencement of Pivotal Trial to Evaluate New Extended Wear Infusion Set

Commencement of Pivotal Trial to Evaluate New Extended Wear Infusion Set

Medtronic plc announced that it received investigational approval from the U.S. Food and Drug Administration (FDA) to proceed with a pivotal trial for a new extended wear infusion set. The goal of the study will be to collect clinical data to support the use of the extended wear infusion set for up to seven days – more than twice the length of time that any infusion set can currently be used. The multi-center, non-randomized, prospective single arm study will enroll up to 150 subjects, aged 18 to 80, with type 1 diabetes on insulin pump therapy.

Infusion sets allow people on insulin pump therapy to deliver insulin under the skin to maintain healthy blood glucose levels. Current generation infusion sets must be changed every two to three days. Using proprietary technology and developed in partnership with ConvaTec’s Unomedical subsidiary, this new infusion set aims to extend patient wear time by using new adhesive technology as well as maintaining insulin stability. An extended wear infusion set could solve a key unmet need in insulin pump therapy by reducing the time and effort currently spent on changing infusion sets. When used with Medtronic insulin pump systems that include 7-day continuous glucose monitors, this new infusion set could allow coordination of changing of the infusion set and sensor at the same time, a feature that would address making insulin pump systems more convenient to use.

“I would love for my son to spend less time thinking about his diabetes and more time living his best life,” said Dani Labriola whose son uses the MiniMedTM 670G system to manage his diabetes. “Changing his set once per week instead of 2-3 times would take away some of that burden and would make a difficult disease easier.”

In the trial, users of the MiniMed 670G system (i.e., pump, sensor and transmitter) will wear each infusion set for up to seven days. The initiation of this trial follows Medtronic’s receipt of an Investigational Device Exemption (IDE) approval from the FDA.

“There have been significant advances made in the three-plus decades with insulin pumps and continuous glucose monitoring (CGM). However, we are still stuck with having patients change the insulin delivery sets every 2-3 days whereas most CGMs are now used longer,” said Satish Garg, M.D., professor of Medicine and Pediatrics and director of the Adult Diabetes Division of Barbara Davis Center of the University of Colorado. “It is time for an infusion set to extend wear to a week and beyond. This is long overdue and will likely improve quality of life for patients on insulin pumps, and many more patients may accept insulin pump as an option.”

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy